- March: $125+ (post-Q1 earnings surge)
- May: $95-100 (profit-taking phase)
- July: $90-95 (Q2 earnings preparation)
- September: $90.91 (finding support)
How to Buy Glaukos Corporation (GKOS) Shares - Investment in Glaukos Corporation (GKOS) Stock
Updated on 10 Sep 2025
Thinking about investing in a company that's revolutionizing eye care? Glaukos Corporation (GKOS) combines medical innovation with strong growth potential—perfect for investors looking beyond traditional healthcare stocks. With groundbreaking products like iDose TR transforming glaucoma treatment, this company touches millions of lives while creating shareholder value. Let's explore everything you need to know about investing in GKOS.
Article navigation
- 📈 Glaukos Stock: Current Price and Market Position
- 🔮 Price Forecast: 2025-2030 Outlook
- ⚠️ Key Risks vs. Positive Signals
- 🛡️ What Should a Beginner Trader Do Today?
- ✅ How to Buy Glaukos Corporation (GKOS) Shares – Step by Step
- 💡 Why Pocket Option Fits New Investors
- 🌍 Glaukos in 2025: Revolutionizing Eye Care
📈 Glaukos Stock: Current Price and Market Position
As of September 10, 2025, Glaukos Corporation (GKOS) trades at $90.91 on the NYSE. Mark your calendar: November 3, 2025, is absolutely critical—that’s when Glaukos releases its Q3 earnings after market close. Historically, these reports have moved prices dramatically.
How Earnings Reports Move GKOS Stock
| Date | Event | Pre-News Price | Post-News Change |
|---|---|---|---|
| Jul 30, 2025 | Q2 Earnings | $94.50 | +8.2% (1 week) |
| Apr 30, 2025 | Q1 Earnings | $88.20 | +12.5% (beat estimates) |
| Feb 2025 | Annual Results | $102.30 | -15.3% (profit concerns) |
| Nov 2024 | Product Launch | $95.80 | +6.8% (iDose TR hype) |
| Aug 2024 | Q2 Earnings | $89.40 | -4.2% (missed targets) |
| May 2024 | FDA Approval | $82.10 | +18.9% (regulatory win) |
Trend Insight: Positive earnings surprises (like Q2 2025) create explosive upside moves. The stock jumped 8.2% after reporting record $124.1 million revenue that beat estimates by 7.4%. However, profitability concerns can trigger sharp declines, as seen in February 2025.
6-Month Price Journey (March-September 2025)
Glaukos shares experienced significant volatility, declining approximately 37-40% year-to-date but showing recent stabilization:
Why the dramatic movement? The stock hit its all-time high of $163.71 on January 23, 2025, but concerns about profitability timelines and MAC reimbursement issues created selling pressure despite strong revenue growth.
Key Drivers
- iDose TR generating ~$31 million quarterly sales
- 30% year-over-year revenue growth
- Transition to dual-growth engine business model
🔮 Price Forecast: 2025-2030 Outlook
- 2025 (Year-End): $127-$131 → STRONG BUY
With raised guidance to $480-486 million revenue and strong iDose TR adoption, analysts see 35-39% upside potential by year-end. - 2026: $145-$155
Continued iDose TR market penetration and potential FDA approvals driving growth. - 2028: $180-$210
Market leadership consolidation in interventional glaucoma space. - 2030: $250-$300
Global expansion and new product pipeline commercialization.
Verdict: Current trading at 43% discount to intrinsic value makes this an exceptional buying opportunity for long-term investors.
⚠️ Key Risks vs. Positive Signals
Risks to Consider
- Profitability timeline: Still reporting net losses (-$0.34 GAAP EPS in Q2)
- Regulatory uncertainty: MAC reimbursement issues affecting some regions
- Market competition: Established players in ophthalmology space
- Volatility: Beta of 0.77 but experienced 44% decline from January highs
Green Lights for 2025
- Record growth: 30% YoY revenue increase to $124.1 million
- Product success: iDose TR generating massive adoption with ~$31M quarterly sales
- Guidance raise: Increased full-year revenue projection to $480-486M
- Market leadership: Pioneer in $1.64B global glaucoma market
- Strong cash: $500 million reserves providing strategic flexibility
🛡️ What Should a Beginner Trader Do Today?
- Dollar-cost average: Invest fixed amounts weekly to avoid timing mistakes
- Set earnings alerts: Monitor November 3rd closely—buy any post-earnings dip
- Think long-term: This is a 3-5 year growth story, not a quick trade
- Diversify properly: Keep GKOS allocation below 10% of your portfolio
Humorous take: “Trading GKOS is like eye surgery—requires steady hands and perfect timing. Blink at the wrong moment and you might miss the opportunity!”
✅ How to Buy Glaukos Corporation (GKOS) Shares – Step by Step
| Step | Action | Why It Matters |
|---|---|---|
| 1 | Choose a trading platform | Ensure it offers NYSE-listed stocks and competitive fees |
| 2 | Open and fund your account | Start with an amount you’re comfortable risking |
| 3 | Search “GKOS” | Use the exact ticker symbol, not just “Glaukos” |
| 4 | Select order type | Use limit orders to control your entry price |
| 5 | Review and confirm | Check commission rates and total cost before executing |
💡 Why Pocket Option Fits New Investors
Pocket Option makes stock investing accessible for everyone:
- Minimum deposit: Just $5 lets you start building your portfolio
- Lightning-fast verification: 1-minute KYC with any ID document
- 100+ withdrawal options: From crypto to bank transfers worldwide
- Fractional shares: Invest in expensive stocks with small amounts
🌍 Glaukos in 2025: Revolutionizing Eye Care
Glaukos Corporation dominates the innovative ophthalmology space with five novel platforms targeting glaucoma, corneal disorders, and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery (MIGS) and continues to lead the $1.64 billion global glaucoma market.
2025 Fun Fact: Glaukos’ iDose TR implant represents such a breakthrough that over 80% of its volume comes from regions with established professional fee schedules—surgeons are literally lining up to use this dropless therapy that eliminates daily eye drops for glaucoma patients!
FAQ
What makes Glaukos different from other medical companies?
Glaukos pioneered Micro-Invasive Glaucoma Surgery and focuses exclusively on innovative ophthalmic treatments, particularly their revolutionary iDose TR implant that delivers continuous medication without daily eye drops.
Is now a good time to invest in GKOS stock?
With the stock trading at a 43% discount to intrinsic value and showing strong revenue growth (+30% YoY), many analysts consider this an attractive entry point for long-term investors.
What are the main risks with investing in Glaukos?
The primary risks include ongoing profitability concerns (still reporting net losses), regulatory changes affecting reimbursement, and competition in the ophthalmology space despite their innovative products.
How often does Glaukos report earnings?
Glaukos reports quarterly earnings with the next report scheduled for November 3, 2025. The company has consistently beaten revenue estimates in recent quarters.
What's the long-term growth potential for GKOS?
Analysts project significant growth, with price targets reaching $250-$300 by 2030 driven by global expansion of their iDose TR technology and new product pipeline developments.
Signals
Sign up for more like this
Customize your newsfeed with content you're actually interested in — get up-to-date personalized newsletter in your inbox.
Your comment
Comments are pre-moderated to ensure they comply with our blog guidelines.